|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Serum PSA was significantly negatively correlated with serum total oxidant status (<i>r</i>= -0.309, <i>p</i> = .003) but there was no significant correlation between PSA and 25(OH)D (<i>p</i> = .383) or total antioxidant levels (<i>p</i> = .233).
|
30084276 |
2019 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical tableaux of high suspicion of neuroendocrine cancer included radiological progression of a metastatic disease without PSA rise, relatively extended metastatic disease associated to a low PSA, disease with non-pulmonary visceral metastases.
|
31414399 |
2019 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the data demonstrate that ONC201 downregulates the expression of key drivers of prostate cancer such as AR-V7 and downstream target genes including the clinically used biomarker PSA (KLK3).
|
29588330 |
2018 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While an elevated PSA significantly increases the risk of men harboring prostate cancer, many men with a persistently elevated PSA have negative prostate biopsies.
|
29808301 |
2018 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AR expression also correlated with downstream targets PSA (KLK3) and PSMA (FOLH1) and increased cell proliferation.
|
29249638 |
2018 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Definitions of prostate-specific antigen (PSA) treatment response to RASND were defined as 6-week PSA <0.2 ng/mL (broad definition) or PSA <0.05 ng/mL (strict definition) in those who had undergone primary prostatectomy, and 6-week PSA level < post-radiotherapy nadir in those who had undergone primary radiotherapy.
|
28548372 |
2017 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We extracted RNA from the initial biopsy and measured PCA3-shRNA2, PCA3 and PSA (qRT-PCR).
|
28380027 |
2017 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, men with higher iPSA are more likely to have a pre-RT PSA greater than 0.5 ng ml(-1) in response to neoadjuvant ADT and are therefore candidates for clinical trials testing newer, more aggressive hormone-ablative therapies.
|
23939133 |
2013 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aberrant expression of KLKs, presented in many human malignancies, highlights the significance of this gene family for early diagnosis, prognosis and monitoring of cancer patients, as it is strongly emphasized by the routine use of PSA (KLK3) for prostate cancer management.
|
20302518 |
2010 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA (hK3) is one of the human kallikreins, and is the most useful tumor marker for prostate cancer screening, diagnosis, prognosis and monitoring. hK2, another prostate-specific kallikrein, has also been proposed as a complementary prostate cancer biomarker.
|
15911097 |
2005 |
|
Salivary Gland Pleomorphic Adenoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As such, preoperative knowledge of f-PSA and c-PSA values and the three ratios provided no additional diagnostic information over standard PSA (t-PSA) values alone.
|
8753736 |
1996 |